About this role
About us:
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
The role:
The Scientist/Senior Scientist, Clinical Pharmacology & DMPK will be the hands-on scientific and operational engine of the clinical pharmacology group, reporting to the Vice President, Clinical Pharmacology & DMPK. You will support Phase 1 clinical pharmacology studies, model-informed dose optimization, and the clinical pharmacology content of global regulatory filings as assets move through clinical development towards registration. You will be a member of a lean, cross-functional development team comprised of representatives from Clinical Operations, Biometrics, Regulatory, CMC and external CROs, and your work will directly shape program strategy and decisions. Additionally, you may have the opportunity to support the nonclinical DMPK-related activities of our drug discovery programs.
The role will be filled at the Scientist or Senior Scientist level depending on experience. Senior Scientists will be expected to own workstreams and vendors more independently and to represent the function on cross-functional teams in collaboration with the VP of Clinical Pharmacology.
Key responsibilities:
Clinical Pharmacology Support
- Collaboratively plan and execute clinical pharmacology or DMPK workstreams to support clinical assets, including the design and execution of Phase 1 clinical pharmacology studies (e.g., SAD/MAD, drug interaction, food effect, QTc, and hepatic/renal impairment studies)
- Provide oversight and guidance for noncompartmental analyses (NCA), population PK, exposure–response, and PK/PD analyses (including relationships with clinically relevant endpoints), working with external modeling and simulation vendors
- Prepare PK and PK/PD datasets, including CDISC-aligned (SDTM PC/PP, ADaM ADPC/ADPP) specifications, with Biometrics and Data Management
- Represent Clinical Pharmacology & DMPK on study and program teams; present results to cross-functional teams and leadership; author and review PK sections of protocols, statistical/PK analysis plans, clinical study reports and regulatory documents (e.g., IB, IND/CTA, DSUR, briefing books, NDA/MAA modules 2.7.2 and 2.6.4/2.6.5); contribute to responses to health authorities
DMPK and nonclinical support
- Perform NCA PK analyses, interpretation and reporting using Phoenix WinNonlin or equivalent tools
- Integrate nonclinical ADME, toxicokinetic and translational data to inform DDI risk assessment and clinical study design
- Participate in the oversight of bioanalytical CROs for method development, validation, and sample analysis under GLP/GCP
- Review bioanalytical plans, validation reports and sample analysis data for quality and data integrity
Additional Support
- Contribute to building fit-for-purpose processes, SOPs, and templates as the company scales toward registration
- Contribute to abstracts, posters and publications; present at external meetings
- Mentor junior staff or contractors as the team grows
Required experience & skills:
- A PhD or PharmD degree in pharmacokinetics, pharmaceutical sciences, pharmacology, bioanalytical chemistry, or a related field with 3+ years of relevant industry experience; or MS degree with 8+ years of relevant industry experience
- Hands-on NCA experience with Phoenix WinNonlin or equivalent software
- Solid understanding of PK/PD, ADME and DDI principles, and how nonclinical data translate to clinical study design
- Working knowledge of ICH, FDA and EMA guidance for clinical pharmacology and bioanalytical method validation, and of GLP/GCP
- Experience working with CROs or external vendors
- Strong organization and attention to detail, with the ability to manage several studies at once
- Strong written and verbal communication skills with a collaborative, team-oriented approach
- Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity
- Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude
Preferred experience & skills:
- Experience with population PK, exposure–response or PBPK modeling (e.g., NONMEM, Monolix, R, Simcyp or GastroPlus)
- Experience supporting regulatory submissions or health authority interactions (IND, NDA/MAA)
- Experience with CDISC PK data standards
- Exposure to cardiovascular, rare disease, or late-stage (Phase 3) programs
- Experience in a small biotech or matrixed environment
Base Salary Range: $130,000 - $185,000
This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E ‑ Verify program to confirm employment authorization for all new hires.
To learn more about E-Verify please review this poster .
